Company Overview of Xention Limited
Xention Limited, a biopharmaceutical company, discovers and develops novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development. It provides XEN-D0101, which utilizes extensive cardiovascular safety monitoring; and XEN-D0103, which demonstrates a very high degree of selectivity over non-atrial ion channels. The company was formerly known as Xention Discovery Ltd. and changed its name to Xention Limited in October 2006. Xention Limited was incorporated in 2002 and is based in Cambridge, United Kingdom.
Unit 5, Quern House
Cambridge, CB22 5LD
Founded in 2002
44 1223 493 900
44 1223 493 901
Key Executives for Xention Limited
Similar Private Companies By Industry
|Abbey Pharma Limited||Europe|
|Absynth Biologics Limited||Europe|
|Acacia Pharma Limited||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Xention Limited, please visit www.xention.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.